CD22 (Ab-807) Antibody

What is CD22 and why is it an important target for immunological research?

CD22 (Siglec 2) is a receptor predominantly restricted to B cells that was initially characterized over 30 years ago and officially named "CD22" in 1984 at the 2nd International workshop in Boston. As a member of the Siglec family, CD22 functions as a negative regulator of B cell receptor (BCR) signaling and plays essential roles in maintaining B cell homeostasis .

CD22 has emerged as a critical research target due to its:

• Role in regulating B cell responses to T cell-independent and T cell-dependent antigens

• Function in modulating Toll-like receptor (TLR) signaling

• Involvement in B cell trafficking and adhesion

• Potential as a therapeutic target for autoimmune diseases like systemic lupus erythematosus (SLE)

This combination of functions makes CD22-targeting antibodies valuable tools for investigating B cell biology, autoimmunity, and immunological disorders .

How does CD22 regulate B cell responses to different antigens?

CD22 regulates B cell responses to multiple antigen types through distinct mechanisms:

• T cell-independent (TI) type 2 antigens: CD22-deficient mice show impaired antibody responses to TI-2 antigens, suggesting a positive regulatory role in these responses .

• Toll-like receptor (TLR) responses: CD22 negatively regulates B cell responses to TLR ligands. CD22-deficient B cells show hyperproliferation when stimulated with TLR3 (poly I:C), TLR4 (LPS), TLR7 (R848), and TLR9 (CpG) agonists . This hyperresponsiveness is associated with increased MHC class II and CD86 expression, suggesting CD22-deficient B cells may become more effective antigen-presenting cells.

• T cell-dependent (TD) antigens: The role of CD22 in TD responses is more complex. Initial studies suggested CD22-deficient mice have normal responses to TD antigens, but later research indicated CD22 plays important roles in germinal center dynamics and memory B cell generation .

Researchers using CD22 (Ab-807) Antibody should consider these diverse roles when designing experiments to investigate specific B cell response pathways.

What are the recommended applications for CD22 (Ab-807) Antibody in B cell research?

Based on CD22's known functions, the CD22 (Ab-807) Antibody can be utilized for:

• Flow cytometry: To identify and isolate B cell populations and subsets

• Immunohistochemistry: To examine CD22 expression in tissue sections

• Functional studies: To investigate the role of CD22 in:

  • BCR signaling modulation

  • TLR response regulation

  • B cell trafficking to gut-associated lymphoid tissues

  • Autoimmune processes

• Therapeutic development: As a model for CD22-targeted immunotherapeutics

When designing experiments, researchers should consider that CD22 is an endocytic receptor that recycles between the cell surface and endosomes, which may affect antibody internalization kinetics and experimental protocols .

How can CD22 (Ab-807) Antibody be used to investigate BCR and TLR signaling crosstalk?

CD22 (Ab-807) Antibody provides a powerful tool to investigate the complex interplay between BCR and TLR signaling pathways. Research has shown that CD22 may regulate TLR signaling through several mechanisms:

• SOCS protein activation: CD22 appears to function during TLR signaling to activate suppressors of cytokine signaling (SOCS1 and SOCS3) that blunt responses to TLR ligands .

• Endosomal regulation: CD22 recycles between the cell surface and endosomes where endosomal TLRs reside, potentially affecting endosomal TLR signaling through changes in CD22 microdomain organization .

• NF-κB pathway modulation: CD22 signaling might interfere with B cell survival and proliferation induced downstream of TLR7 by affecting NF-κB activation and pro-survival molecules .

Methodological approach for studying this crosstalk:

• Use CD22 (Ab-807) Antibody to engage CD22 on human B cells while stimulating with TLR7/9 ligands

• Monitor changes in cytokine production (decreased IL-6, increased IL-10)

• Assess MAPK/ERK phosphorylation, which can be triggered by CD22 engagement

• Examine PRDM1 (Blimp1) expression, which is inhibited by CD22 engagement during TLR7 stimulation

This experimental paradigm allows researchers to dissect how CD22 engagement affects TLR-driven B cell activation, particularly relevant for understanding autoreactive B cell responses.

What approaches can distinguish between cis and trans interactions of CD22 using CD22 (Ab-807) Antibody?

Distinguishing between cis (same cell) and trans (different cell) interactions of CD22 is crucial for understanding its regulatory functions. CD22 (Ab-807) Antibody can facilitate this investigation through several approaches:

• Synthetic multivalent antigen systems: Researchers have designed polymeric antigens that display both a BCR-binding epitope and a CD22 ligand to test trans interactions. If only cis interactions are relevant, CD22 will be masked and the antigens will interact only with the BCR .

• Liposomal nanoparticles (STALs): SIGLEC-engaging Ag-liposomes bearing high-affinity ligands for CD22 have been used to deliver antigens to B cells while engaging CD22 in trans. These can be combined with CD22 antibodies to investigate the signaling consequences .

• CD22 ligand-deficient systems: Compare experiments using ST6Gal1-deficient B cells (which lack CD22 ligands) with wild-type cells. For example, ST6Gal1-deficient B cells have normal responses to LPS and CpG despite lacking CD22 cis ligands, suggesting trans interactions may be more important for certain functions .

• Chimeric antibody constructs: Triple chimeras that simultaneously engage BCR, CD22, and FcγRIIb can selectively target autoreactive B cells and have been used to inhibit autoantibody production, suggesting a therapeutic potential for engineered CD22 trans interactions .

How does CD22 contribute to B cell memory formation and how can CD22 (Ab-807) Antibody help investigate this process?

Research indicates that CD22 plays a critical role in the generation of memory B cells, particularly in response to T cell-dependent antigens. CD22 (Ab-807) Antibody can be instrumental in investigating this function:

• Germinal center B cell dynamics: CD22-deficient B cells can develop into germinal center (GC) B cells but fail to efficiently differentiate into memory B cells or long-lived plasma cells (LLPCs) . This defect is associated with failure to develop a subset of CXCR4+CD38+ GC B cells, which may be precursors to memory B cells and LLPCs.

• Experimental approach:

  • Track GC B cell development using CD22 (Ab-807) Antibody in combination with other markers

  • Examine the formation of CXCR4+CD38+ GC B cell subsets

  • Monitor antibody persistence over time as an indirect measure of LLPC formation

  • Compare CD22-sufficient and CD22-deficient B cells using adoptive transfer experiments

• Conflict in literature: While CD22-deficient B1-8hi B cells (with BCR specific for NP) develop into GC B cells but fail to become memory cells or LLPCs, other studies with different antigens show varied results. This suggests CD22's role may depend on the nature of the antigen or adjuvant used .

This research area particularly highlights the need to consider antigen-specific effects when using CD22 (Ab-807) Antibody to study memory B cell formation.

What are the optimal protocols for using CD22 (Ab-807) Antibody in flow cytometry?

When using CD22 (Ab-807) Antibody for flow cytometry, researchers should consider the following technical aspects:

• Expression pattern considerations:

  • CD22 is predominantly restricted to B cells

  • Expression varies among B cell subsets

  • CD22 molecules are organized in nanodomains, regulated by interactions with CD45

  • CD22 recycles between the cell surface and endosomes

• Sample preparation optimizations:

  • Fresh cells are preferable due to CD22's recycling nature

  • If cells must be fixed, use mild fixation to preserve epitope recognition

  • Include proper blocking steps to reduce non-specific binding

  • Consider the impact of different buffers on CD22 nanodomain organization

• Panel design strategies:

  • Combine with other B cell markers (CD19, CD20) for accurate B cell identification

  • Include markers that help identify specific B cell subsets (naïve, memory, germinal center)

  • Consider including markers for CD22 ligands (α2,6-linked sialic acids) when studying cis/trans interactions

  • When studying autoimmunity models, include markers for transitional (TR) B cells, which expand with increased TLR7 expression

• Controls:

  • Include CD22-knockout or CD22-deficient cells as negative controls when available

  • Use isotype controls to determine background staining

  • Consider including ST6Gal1-deficient cells when studying CD22-ligand interactions

How should researchers incorporate CD22 (Ab-807) Antibody into studies investigating autoimmunity?

CD22 plays important roles in maintaining B cell tolerance, and CD22 (Ab-807) Antibody can be effectively utilized in autoimmunity research through the following approaches:

• Mechanistic studies:

  • Examine how CD22 engagement affects TLR7-driven B cell activation, which is implicated in RNA-associated autoimmunity

  • Investigate CD22's role in inhibiting PRDM1 (Blimp1) expression to limit plasma cell differentiation

  • Study CD22's effect on cytokine production: inhibition of IL-6 and promotion of IL-10

• Experimental autoimmune disease models:

  • Accelerated models: CD22 deficiency accelerates autoimmunity in mice carrying the Yaa locus (TLR7 duplication)

  • Transgenic models: Anti-DNA transgenic (D42HTg) mice with CD22 deletion show rescue of autoreactive cells from peripheral tolerance

  • Consider "gene dosage" effects, as even heterozygous CD22+/- mice show increased autoantibody production

• Therapeutic approaches:

  • CD22-targeted STALs (SIGLEC-engaging Ag-liposomes) for inducing antigen-specific tolerance

  • Chimeric antibodies coupling DNA mimotope peptides with CD22-binding STN peptide

  • CD22 antibody treatment for B cell depletion/reprogramming in autoimmune settings

• Technical considerations:

  • Account for strain-specific CD22 alleles when designing experiments

  • The Cd22a allele (in C57BL/6, 129) differs from Cd22b (in DBA/2J, DBNl, NZB, NZC)

  • These allelic differences may affect antibody binding and functional outcomes

What approaches can help investigate CD22's role in regulating TLR signaling using CD22 (Ab-807) Antibody?

CD22 has emerged as an important regulator of TLR signaling in B cells. Researchers using CD22 (Ab-807) Antibody to investigate this function should consider these methodological approaches:

• In vitro B cell stimulation assays:

  • Compare proliferation responses to various TLR ligands (TLR3/poly I:C, TLR4/LPS, TLR7/R848, TLR9/CpG) in the presence or absence of CD22 engagement

  • Monitor activation markers: CD22-deficient B cells show enhanced upregulation of MHC class II and CD86 in response to TLR stimulation

  • Assess cytokine production profiles (IL-6, IL-10) following TLR stimulation with and without CD22 engagement

• Signaling pathway analysis:

  • Examine SOCS1 and SOCS3 activation, which CD22 appears to promote during TLR signaling

  • Investigate MAPK/ERK phosphorylation triggered by CD22 engagement

  • Assess NF-κB activation and pro-survival pathways that may be affected by CD22

• Endosomal co-localization studies:

  • Since CD22 recycles between the cell surface and endosomes (where TLR7/9 reside), investigate potential co-localization

  • Study whether CD22 antibody-mediated internalization affects endosomal TLR signaling

  • Examine potential interactions between CD22 and CD72, which binds to endogenous TLR7 ligand Sm/RNP and inhibits TLR7-driven B cell responses

• Experimental model considerations:

  Model System	Experimental Approach	Expected Outcome	Relevant Controls
  Wild-type B cells	CD22 antibody engagement + TLR stimulation	Reduced proliferation, decreased IL-6, increased IL-10	Isotype control antibody
  CD22-deficient B cells	TLR stimulation	Hyperproliferation, enhanced MHC-II and CD86 upregulation	Wild-type B cells
  ST6Gal1-deficient B cells	TLR stimulation	Normal responses to LPS and CpG	Wild-type B cells
  MyD88-deficient system	CD22 antibody + poly I:C (TLR3)	Determine MyD88-independent effects	MyD88-sufficient controls

This methodological framework enables researchers to comprehensively investigate the complex relationship between CD22 and TLR signaling pathways, with implications for understanding both normal B cell responses and autoimmune conditions.

How can CD22 (Ab-807) Antibody contribute to the development of novel therapeutic approaches?

CD22-targeting strategies have shown promising therapeutic potential, and CD22 (Ab-807) Antibody can contribute to developing these approaches through:

• SIGLEC-engaging Ag-liposomes (STALs):

  • Liposomal nanoparticles bearing high-affinity CD22 ligands deliver antigens while engaging CD22

  • Induce antigen-specific immunological tolerance through CD22-mediated inhibition of BCR signaling

  • Demonstrated effectiveness in hemophilia A model by inhibiting anti-FVIII antibody responses

  • Recent development of STALs targeting human CD22 in humanized CD22 transgenic mice

• Chimeric antibody constructs:

  • Triple chimeras coupling DNA mimotope peptide and CD22-binding STN peptide to mouse IgG backbone

  • Selectively target autoreactive B cells through simultaneous engagement of BCR, CD22, and FcγRIIb

  • Inhibit anti-DNA antibody production and delay disease development in lupus models

• B cell reprogramming strategies:

  • CD22-targeting shown to partially deplete and reprogram B cells in autoimmune NOD mice

  • Reversed development of autoimmune diabetes

  • CD22 engagement inhibits PRDM1 (Blimp1) expression and limits plasma cell differentiation

• Cytokine modulation:

  • CD22 engagement shifts cytokine production from pro-inflammatory (IL-6) to regulatory (IL-10)

  • Could help restore immune balance in autoimmune settings

Research with CD22 (Ab-807) Antibody in these contexts can help develop targeted therapies that specifically modulate autoreactive B cells while maintaining protective immunity.

What role does CD22 play in B cell trafficking and how can this be investigated?

Recent research has uncovered a surprising role for CD22 in B cell homing to gut-associated lymphoid tissues, providing new avenues for investigation using CD22 (Ab-807) Antibody:

• Gut-associated lymphoid tissue (GALT) homing:

  • The St6Gal1 ligand for CD22 is selectively expressed on mouse Peyer's patch (PP) high endothelial venules (HEVs)

  • This expression pattern is not seen on peripheral lymph node HEVs or capillary endothelial cells

  • Homing to Peyer's patches is dramatically reduced in both CD22-deficient and ST6Gal1-deficient mice

  • Similar binding patterns observed in human mucosal lymphoid organs, suggesting conserved function

• Experimental approaches:

  • In vivo trafficking studies comparing wild-type, CD22-deficient, and ST6Gal1-deficient B cells

  • Ex vivo adhesion assays using tissue sections containing HEVs from different anatomical locations

  • Competitive homing assays with differentially labeled B cell populations

  • Intravital microscopy to directly visualize B cell trafficking in real-time

• Potential applications:

  • Understanding compartmentalized immune responses in mucosal tissues

  • Developing targeted delivery strategies for oral vaccines or mucosal immunomodulatory therapies

  • Investigating how alterations in CD22-dependent trafficking might contribute to gut-associated autoimmunity

This relatively new understanding of CD22's role in trafficking opens exciting research directions beyond its traditional characterization as a BCR signaling regulator.

Human clinical studies with the anti-CD22 antibody epratuzumab have shown that CD22 engagement specifically inhibits the expression of Blimp1 in response to TLR7 stimulation, limiting B cell differentiation into plasmablasts and modulating cytokine production in ways that could benefit patients with autoimmune conditions .

What are common challenges when working with CD22 (Ab-807) Antibody and how can they be addressed?

Researchers working with CD22 (Ab-807) Antibody may encounter several technical challenges that require specific optimization strategies:

• Strain-specific CD22 allelic variations:

  • The Cd22 gene has at least two alleles with distinct polypeptide coding sequences

  • The Cd22a allele is expressed in C57BL/6 and 129 strains

  • The Cd22b allele is found in DBA/2J, DBNl, NZB, and NZC mice

  • Solution: Verify antibody specificity for the particular CD22 allele in your experimental strain

• CD22 nanodomain organization effects:

  • CD22 molecules are organized in nanodomains regulated by interactions with CD45

  • Experimental manipulations may alter these interactions and affect antibody binding

  • Solution: Consider using gentle cell isolation procedures and appropriate buffers to maintain native organization

• Recycling between surface and endosomes:

  • CD22 constantly recycles between the cell surface and endosomes

  • May affect antibody binding kinetics and internalization rates

  • Solution: Account for internalization in experimental timelines and consider temperature effects on recycling rates

• Ligand masking:

  • CD22 can be masked by cis interactions with sialylated ligands on the same cell

  • May affect antibody accessibility to certain epitopes

  • Solution: Consider using neuraminidase treatment to remove sialic acids when appropriate

• Functional redundancy with other Siglecs:

  • Some functions of CD22 may be compensated by other Siglec family members, particularly Siglec-G

  • May complicate interpretation of CD22-specific effects

  • Solution: Consider double knockout/inhibition experiments when investigating certain B cell functions